Liminatus Pharma Announces Nasdaq Delisting Notification
Liminatus Pharma received a formal delisting notice from Nasdaq after failing to regain compliance with market value listing rules by the May 18, 2026 deadline. The company failed to meet the $50 million market value of listed securities and $15 million market value of publicly held shares requirements.
Key figures
- Appeal deadline
- May 27, 2026
- Suspension date
- May 29, 2026
- Mvls requirement
- $50,000,000
- Mvphs requirement
- $15,000,000
- Compliance deadline
- May 18, 2026
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.